Adocia walks away empty-handed in latest Lilly IP dispute

23 August 2019
adocia_large

The American Arbitration Association Tribunal has dismissed claims from France’s Adocia (Euronext: ADOC) that Eli Lilly (NYSE: LLY) misappropriated and misused company secrets.

The tribunal also blocked a countersuit from Lilly, stating that Adocia concealed the relevant discoveries and confidential information at the heart of the claims.

The decision should mark the final twist in a long-running  legal dispute between the firms, arising from a collaborative research and license agreement in the area of diabetes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology